Inclusion in phase 1 trials in oncology: 2 studies in progress.

A Study of LY3200882 in Participants With Solid Tumors, implemented on June 6, 2018.

A Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancer, implemented on June 6, 2018. 2 patients included to date.